AbClon Inc
KOSDAQ:174900
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AbClon Inc
KOSDAQ:174900
|
KR |
|
A
|
Asia Plastic Recycling Holding Ltd
TWSE:1337
|
CN |
|
S
|
Sarepta Therapeutics Inc
LSE:0L35
|
US |
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
N
|
Nutroganics Inc
OTC:NUTTQ
|
US |
|
F
|
Fagron NV
LSE:0HNZ
|
BE |
|
Zvelo Inc
OTC:ZVLO
|
US |
AbClon Inc
AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. The company is headquartered in Seoul, Seoul and currently employs 60 full-time employees. The company went IPO on 2017-09-18. The firm developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The firm's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The firm distributes its products within domestic market and to overseas markets.
AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. The company is headquartered in Seoul, Seoul and currently employs 60 full-time employees. The company went IPO on 2017-09-18. The firm developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The firm's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The firm distributes its products within domestic market and to overseas markets.
